P2.14-05 A Phase II Study of Sintilimab Combined with Concurrent Chemoradiotherapy in Patients with Limited-Stage Small Cell Lung Cancer:SINCE-01 Trial

For patients with limited stage disease small cell lung cancer(LD-SCLC), concurrent chemoradiotherapy is the standard treatment. However,most patients have local recurrence or distant metastasis about 1 year after treatment, and the median PFS is only about 12 months. Tumor immune checkpoint therapy has made great breakthroughs in recent years. This study is to investigate the efficacy and safety of sintilimab combined with concurrent chemoradiotherapy in LD-SCLC patients.